Impact of Allograft Steatosis on Cardiovascular Outcomes

AbstractPurpose of ReviewCardiovascular events are among the most consequential long-term outcomes in liver transplant recipients. While underlying non-alcoholic fatty liver disease has been independently associated with unfavorable cardiovascular outcomes and increased mortality, it is unclear yet if the same holds true for allograft steatosis. We here review the available data on cardiovascular outcomes after liver transplant with specific focus on allograft steatosis.Recent FindingsTwo subtypes of hepatic allograft steatosis exist, recurrent and de novo, and both are common. Although the current data suggest an association between allograft steatosis and atherogenic lipid profile, they have yet to reveal a negative impact of allograft steatosis on cardiovascular outcomes or mortality.SummaryTargeting the metabolic risk factors in this patient population mainly via weight loss can improve outcomes. Use of angiotensin-converting enzyme might be protective against hepatic steatosis. More investigations into long-term outcomes of allograft steatosis with larger studies are needed.
Source: Current Transplantation Reports - Category: Transplant Surgery Source Type: research

Related Links:

Publication date: Available online 19 July 2019Source: European Journal of RadiologyAuthor(s): Claire Boudinaud, Armand Abergel, Juliette Joubert-Zakeyh, Mikael Fontarensky, Bruno Pereira, Benoit Chauveau, Jean Marc Garcier, Pascal Chabrot, Louis Boyer, Benoît MagninAbstractPurposeGiven the growing prevalence of obesity and metabolic syndrome, the management of hepatic steatosis, especially its quantification, is a major issue. We assessed the quantification of liver steatosis using four different MR methods, in order to determine the one that is best correlated with the reference method which consists of histologica...
Source: European Journal of Radiology - Category: Radiology Source Type: research
Authors: Theodotou M, Fokianos K, Moniatis D, Kadlenic R, Chrysikou A, Aristotelous A, Mouzouridou A, Diakides J, Stavrou E Abstract The aim of the present study was to investigate the effect of a micronized formulation of trans-resveratrol in humans with non-alcoholic fatty liver disease (NAFLD). Trans-Resveratrol has been used in the form of micronized formulation, which is better absorbed, has strong antioxidants effects, is more effective than plain resveratrol formulations and is circulated on the market as a food supplement. Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a stilbenoid and a phytoalexin prod...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Conclusion: NAFLD is emerging as a predominant etiology of CLD in India, followed by ALD, HBV, and HCV. However, significant regional differences regarding predominant etiology was noted within the country. It was further noted that significant number of patients had advanced fibrosis based on VCTE assessment. This study emphasizes the need for appropriate risk evaluation and early assessment of severity of liver disease, for adequate disease management. PMID: 31315327 [PubMed - in process]
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. Steroid hormones and bile acids are potent regulators of hepatic carbohydrate and lipid metabolism. Steroid 5 β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and catalyzes a fundamental step in bile acid synthesis.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research
ConclusionProtective gut microbiota associates with increased specific secondary BAs, which likely inhibit lipogenic pathways and enhance bile flow in the liver. This novel cross ‐talk between gut and liver, via plasma BAs, that promotes protection against NAFLD may have clinical and nutritional relevance.This article is protected by copyright. All rights reserved
Source: Molecular Nutrition and Food Research - Category: Food Science Authors: Tags: Research Article Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 24% of the global adult population. NAFLD is a major risk factor for the development of cirrhosis and hepatocellular carcinoma, as well as being...
Source: Clinical Epigenetics - Category: Research Authors: Tags: Review Source Type: research
Conclusion SGLT-2i treatment improved the liver function test results and reduced the body weight in NAFLD patients over a period of 12-24 months. This improvement was greater in patients with higher ALT values at baseline than in those with lower values. PMID: 31308341 [PubMed - in process]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Conclusion: The presence of the PNPLA3 G allele is associated with a risk of NAFLD. Our study shows that subjects with variant PNPLA3 are not only at increased risk for the development and progression of NAFLD, but also have increased insulin resistance. PMID: 31304703 [PubMed - in process]
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver illness with a genetically heterogeneous background that can be accompanied by considerable morbidity and attendant health care costs. The pa...
Source: BMC Medicine - Category: Internal Medicine Authors: Tags: Research article Source Type: research
In this issue, Srivastava et al. evaluated a pathway for the management of patients with non-alcoholic fatty liver disease (NAFLD), using blood tests to stratify patients in primary care in order to improve detection of cases of advanced fibrosis and cirrhosis. They studied 3,000 patients seen in primary care using a 2-step algorithm combining the use of FIB-4 followed by the ELF ™ test if required. Use of this approach detected 5-fold more cases of advanced fibrosis and cirrhosis. Unnecessary referrals from primary care to secondary care fell by 70–80%.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Desk Source Type: research
More News: Alcoholism | Bone Graft | Cardiology | Cardiovascular | Fatty Liver Disease (FLD) | Heart | Liver | Liver Disease | Liver Transplant | Non-alcoholic Fatty Liver Diseases (NAFLD) | Study | Transplant Surgery | Transplants | Urology & Nephrology | Weight Loss